Ilgenli 2007.

Methods	A 4 hours before‐after study of methylphenidate acute effect on QT intervals
Participants	Number of participants screened: not stated Number of participants included: 25 Number of participants followed up: 22 Number of withdrawals: 3 Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: mean 9.4, range 7‐15 years old IQ: no intellectual disability Sex: 11 males, 11 females Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Turkey Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria Age between 7 and 15 years ADHD based on DSM‐IV. Only symptoms rated as 'often' or 'very often' were counted toward the diagnosis No history of intellectual disability, gross neurologic abnormality or Tourette syndrome Patient decision to participate in a stimulant medication trial on clinical grounds
Interventions	Methylphenidate type: not stated Methylphenidate dosage:10 mg Administration schedule: not stated Duration of intervention: 2 hours Treatment compliance: not stated
Outcomes	Non‐serious adverse events: ECG were taken 2 hours before and 2 hours after administration of methylphenidate QT dispersion was measured as the difference between maximum and minimum QT intervals QTc was calculated with the use of Bazett's formula
Notes	Sample calculation: not stated Ethics approval: yes, approved by the institutional ethical committee Funding/vested interests/authors' affiliations: not stated Key conclusions of the study authors: this study reveals that methylphenidate reduces QT dispersion during the acute period, shortly after its administration. Data support the reliability of this drug in terms of early arrhythmia Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no Supplemental information received through personal email correspondence with the authors in November 2013 (Ilgenli 2013 [pers comm])